SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is gaining traction, particularly within the Solana ecosystem, with community members emphasizing a bullish outlook. Conversations highlight the importance of holding through dips, with many expressing confidence in a future breakout. The community buzz includes mentions of potential burns, NFT staking, and the phrase "WAGMI".

USDC is a fully collateralized US dollar stablecoin. USDC is the bridge between dollars and trading on cryptocurrency exchanges. The technology behind CENTRE makes it possible to exchange value between people, businesses and financial institutions just like email between mail services and texts between SMS providers. We believe by removing artificial economic borders, we can create a more inclusive global economy.

USD Coin

USDC is trending amid discussions of its utility and role in the crypto ecosystem, particularly on the Solana network, where it facilitates trading and provides stability. Community members are actively discussing opportunities to earn rewards and passive income through USDC, with some highlighting its integration with projects like $BROKE and its increasing use in real-world applications. There's also chatter about regulatory developments and potential partnerships that could further solidify USDC's position in the market.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending with mixed sentiment as the community discusses potential pullbacks and recovery, while also mentioning interest in meme coins within its ecosystem. Some traders are highlighting accumulation patterns and potential breakout opportunities for Solana-based projects. The broader conversation includes speculation around ETF narratives and capital inflows.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending as the community discusses its potential for recovery after a challenging year, with some pointing to strong developer activity and rising whale accumulation as positive indicators. While some community members express concerns about its performance and tokenomics, others highlight its unique technology and potential for future growth, especially with the launch of AI tools like Caffeine AI. Discussions also include the impact of broader market trends and potential listings on major exchanges.

What Is Pi Network? Pi Network is a social cryptocurrency, developer platform, and ecosystem designed for widespread accessibility and real-world utility. It enables users to mine and transact Pi using a mobile-friendly interface while supporting applications built within its blockchain ecosystem.  Supply Model and Mining Mechanism The Maximum Supply of Pi is 100 billion tokens. The Maximum Supply is comprised of the following: 65 Billion tokens (or 65%) are allocated for all community mining rewards; 10 billion (10%) are allocated for foundation reserves; 5 billion (5%) are allocated for liquidity purposes; and 20 billion (20%) are allocated for the Core Team. Each allocation mentioned above tracks the community Migrated Mining Rewards issuance pace, so the proportions of each allocation in the total supply remains the same at any given time.   The Effective Total Supply of Pi—the total Pi supply at the current time—allocates Pi proportionally the same as the Maximum Supply. Since every allocation tracks the Migrated Mining Rewards of the community, the Effective Total Supply can be calculated by dividing the current Migrated Mining Rewards of Pi on the Mainnet blockchain by 65%. The other allocations within the Effective Total Supply can then be calculated based on the same proportions as the Maximum Supply, e.g. at most 10% of the Effective Total Supply is available in the foundation reserve, 5% of the Effective Total Supply is available for liquidity purposes, and 20% of the Effective Total Supply is available for the Core Team. This remains true despite the fact that all tokens were minted at the genesis as technically required by the blockchain protocol.  Circulating Supply includes all Migrated Mining Rewards and all tokens that entered circulation from other buckets of the allocations, which at its maximum could be summed up to equal the Effective Total Supply.   Pi’s mining rewards are distributed based on an issuance formula that follows a declining exponential model defined in the Pi whitepaper. Users can increase the amount of mining rewards they receive based on their individual contributions to the network, like Security Circles, using utility-based Pi apps, running Nodes, etc. For each month, the amount of Pi to be distributed as mobile balance is capped and determined by the model, regardless of how many people or how many types of mining rewards there are during the month. The capping is achieved by the design of a system-wide base mining rate, and each type of mining rewards to each individual are just a multiplier of this base mining rate. As the monthly supplies always diminish, the base mining rate generally decreases over time.   Fewer Pi may also be issued because the real Pi issuance on the blockchain depends on Pioneers passing KYC and completing all steps required for migration to the Mainnet. Despite all efforts to facilitate and remind Pioneers to complete those required steps, there are always dropoffs along the way, resulting in less than all outstanding mobile balances to be issued on the blockchain. Because of this mechanism, the community issued amount (Migrated Mining Rewards) on the blockchain will likely be closer and closer to a line lower than the 65 billion. This is thus the reason for the variable Effective Total Supply which incorporates this effect. Effective Total Supply results from all Migrated Mining Rewards divided by 65%, as opposed to the Maximum Supply of 100 billion.  Ecosystem and Adoption Pi Network has built an integrated ecosystem that facilitates real-world transactions and decentralized applications. Pi can be used as a medium of exchange for goods and services, including online commerce and local brick-and-mortar businesses.  Users can engage with Core Team and community-built apps in the Pi ecosystem through the Pi Browser, where integrated features like the Pi Wallet provide a seamless experience. Events like PiFest 2024 showcased Pi’s growing adoption, with over 27,000 active sellers and 28,000 test merchants across 160 countries.  Who Are the Founders of Pi Network? Pi Network was founded by Dr. Nicolas Kokkalis and Dr. Chengdiao Fan, both of whom have PhDs from Stanford University and a passion for improving human lives through technology.  Dr. Nicolas Kokkalis is a Stanford PhD in EE and postdoc in CS with research on distributed systems and human-computer interaction. His work focuses on combining distributed systems and human computer interaction to bring cryptocurrency to everyday people. As a strong and long-term believer of the technical, financial and social potential of cryptocurrencies, he is determined to move them beyond their current limitations and is committed to bringing the power of blockchain to more people.  Dr. Chengdiao Fan holds a Stanford PhD in Anthropological Sciences, harnessing social computing to unlock human potential on a global scale. Chengdiao is building Pi Network to mobilize individuals all over the world to participate and be rewarded for their contributions, and establish an inclusive ecosystem for global citizens to unleash and capture their own agency, and in turn create utilities and productions for society and the world.  Compliance and Identity Verification Pi Network follows a one-account-per-person policy through its Know Your Customer (KYC) solution. This system combines machine automation and human verification to authenticate user identities while preserving privacy.  The KYC process emphasizes real individuals, combats fraudulent activities and enables fair participation in the mining process of the network. Pi’s identity verification approach balances scalability, security, and accessibility, allowing millions of users worldwide to validate their accounts while maintaining regulatory compliance.

Pi Network

Pi Network is currently trending amid community discussions around its potential and future utility. While some speculate on upcoming exchange listings and price predictions, others remain skeptical due to concerns about unverified balances and lack of clear utility. Overall, community members are actively debating the project's long-term viability.

Monero

Monero is trending as community members discuss its potential as a leading privacy coin and its unique position in the crypto landscape. Recent price action and technical analyses are fueling speculation about potential rallies, with some suggesting it's undervalued compared to Bitcoin. Discussions also involve Monero's role in providing financial privacy, especially in light of increasing regulation and interest in decentralized solutions.

Basic Attention Token (BAT) is an open-source, decentralized ad exchange platform built on Ethereum platform. Basic Attention Token held an initial coin offering on May 31, 2017 for its eponymous ERC-20 utility token, raising approximately $35M USD at the time in less than 30 seconds. The Basic Attention Token aims to fix digital advertising, which is broken, fraudulent and opaque.   Basic Attention Token work by having advertisers pay BAT to website publishers for the attention of users. The BAT token is designed to correctly value and price user attention within the platform. The Basic Attention Token comprises various components, including attention measurement systems, analytics dashboards and machine learning algorithms. Integration of BAT into a given host application involves implementing BAT Ads, a system that matches and displays ads to users based on locally stored data. Ad targeting is performed wholly on-device, removing the need for third-party tracking. BAT is focused on the Brave browser. Brave is an open-source, privacy-centered browser designed to block trackers and malware. It utilizes blockchain technology to anonymously and securely track user attention, which translates into rewards for publishers.  A user's attention, meaning his or her focused mental engagement on digital content like advertisements, is logged through Brave. The makers of BAT indicate that the user's private data and tracking information is stored only on the user's device, ensuring that it is anonymous and private.  Created back in 2016, the Basic Attention Token has one of the biggest names behind it, that of Brendan Eich, the creator of JavaScript and the legendary co-founder of Mozilla. Other noteworthy team members include Brian Bondy, lead developer and co-founder of Brave and Scott Locklin, senior engineer, and co-founder of Kerf Software."  Basic Attention Token is created by the team that built the Brave browser, an open-source, privacy-focused browser that blocks ads and trackers. The browser measures user attention and rewards publishers for users attention.   Use the Brave browser to protect your privacy and support CoinGecko at the same time: https://brave.com/coi600

Basic Attention Token

Basic Attention Token is trending as the community discusses its potential breakout and real-world utility through the Brave Browser.  Enthusiasm is building around the potential for increased adoption and partnerships, with some speculating on a significant price increase. Discussions also highlight chatter on 4chan and Grayscale's prior interest.

Volatility Shares Trust - 2x Bitcoin Strategy ETF

Volatility Shares 2x Bitcoin Strategy ETF

BITX is trending as traders discuss its leveraged exposure to Bitcoin, with many focusing on potential entry points and swing trading strategies amidst Bitcoin's price fluctuations. Community members are also closely watching for dividend announcements and analyzing potential impacts from broader market and economic factors. Some traders are expressing concerns about potential volatility decay and the ETF's performance relative to Bitcoin's price movements.

Investment Managers Series Trust II - Tradr 2X Long RGTI Daily ETF

Tradr 2X Long RGTI Daily ETF

RGTU is trending amid discussions about its underlying asset, $RGTI, and its potential for volatility around upcoming earnings. The community is actively trading RGTU as a leveraged play on Rigetti Computing, with some noting substantial overnight gains and discussing strategies involving both long and short positions. Some traders are pointing to a possible stock split.

Trump For President

Trump Crypto is trending amidst community discussions about its potential and future prospects, with some speculating on possible price movements.  Broader conversations involve connections between Trump, crypto, and political narratives.  Some traders are expressing bullish sentiment while others suggest caution.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues

Agios posts a narrower-than-expected third-quarter loss as Pyrukynd drives a 44% revenue rise, with potential label expansions on the horizon.

Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of +7.77% and +27.69%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia

Agios shares tank as the FDA extends the review period for Pyrukynd in thalassemia by three months, pushing the final ruling to Dec. 7, 2025.

Agios Pharmaceuticals, Inc. (AGIO) announced on Thursday that the U.S. Food and Drug Administration has extended the review period for its drug Pyrukynd, intended for the treatment of adult patients with thalassemia, by three months.Thalassemia is a rare, inherited blood disease that affects the production of the protein hemoglobin in red blood cells. By disrupting hemoglobin production, thalassemia reduces the number of circulating red blood cells and shortens their lifespan, resulting in anemia, fatigue, and severe complications.While the FDA was initially expected to decide on the company’s application for Pyrukynd in treating thalassemia by September 7, its decision is now <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.agios.com/news-releases/news-release-details/agios-provides-update-us-pdufa-goal-date-pyrukyndr-mitapivat">expected</a> by December 7. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AGIO">AGIO stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:585/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_04_at_10_30_42_AM_png_307a186918.webp" alt="AGIO's Sentiment Meter and Message Volume as of 10:30 a.m. ET on Sept. 4, 2025 | Source: Stocktwits" width="585" height="62"><figcaption>AGIO's Sentiment Meter and Message Volume as of 10:30 a.m. ET on Sept. 4, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that these are circumstances beyond the company's control.<stembedurl>https://stocktwits.com/forprofit12/message/627455227</stembedurl>A pessimistic user, however, called for selling the company's shares.<stembedurl>https://stocktwits.com/Jadek6/message/627455837</stembedurl>In the original application, the company had described the risk of hepatocellular injury with the drug. However, the firm stated on Thursday that it has submitted a proposed Risk Evaluation and Mitigation Strategy (REMS) in response to a recent information request from the agency.The extension in date of the FDA’s decision is not the result of new or additional efficacy or safety data requested by the FDA or submitted by Agios, but a result of the new REMS submission, the company said. It further termed the REMS submission a major amendment to its original application.“We remain confident in the favorable benefit-risk profile of PYRUKYND in thalassemia,” said CEO Brian Goff. &nbsp;As per Agios, approximately 6,000 adult patients are diagnosed with thalassemia in the U.S.BofA subsequently lowered its price target on Agios Pharmaceuticals to $51 from $52 while keeping a ‘Buy’ rating on the shares. The firm noted that the extension was not the result of new data requested by the FDA or submitted by the company. BofA still views approval in thalassemia as likely given its key opinion leader checks and the strength of data from late-stage trials supporting the application. As such, Agios remains one of the firm's top picks even with the delay, it said.Pyrukynd is already approved for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency. Pyruvate kinase (PK) deficiency is a rare, inherited disorder causing chronic hemolytic anemia in adults, where red blood cells break down too quickly due to a lack of the PK enzyme, resulting in low red blood cell count.AGIO stock is up by 6% this year but down by over 22% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/fda-says-no-advisory-commitee-meeting-required-for-aquestive-oral-epinephrine-film/chwd20pRdYB">FDA Says No Advisory Committee Meeting Needed For Aquestive’s Oral Epinephrine Film</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More 

While the FDA was originally expected to decide on the company’s application for Pyrukynd in treating thalassemia by September 7, its decision is now expected by December 7. 

Equity

Why Is Vertex (VRTX) Up 6.9% Since Last Earnings Report?

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Retail chatter around Agios Pharmaceuticals spiked Tuesday after the company said that Saudi Arabia’s Food and Drug Authority (SFDA) approved Pyrukynd (mitapivat) for the treatment of adult patients with alpha- or beta-thalassemia, regardless of transfusion status.The approval was granted under the SFDA’s Breakthrough Medicines Program and is based on results from the global Energize and Energize-T Phase 3 trials.&nbsp;<a href="https://stocktwits.com/symbol/AGIO">Shares of Agios Pharmaceuticals</a> closed 3.3% higher at $36.16 on Monday, with the stock rising another 2% in after-hours trading to $36.88.Agios had partnered with NewBridge Pharmaceuticals in 2024 to support regional commercialization efforts across the Gulf Cooperation Council (GCC), including the UAE, Kuwait, Qatar, Oman, and Bahrain.However, the milestone approval came alongside new safety scrutiny in the U.S. market.&nbsp;Leerink analyst Andrew Berens noted that three newly listed deaths involving Pyrukynd appeared in the FDA’s Adverse Event Reporting System (FAERS) in July, bringing the total to four since launch.Two of the July cases were in young patients. Berens called the developments “potentially concerning” but cautioned that FAERS entries often lack key details and context.In a regulatory filing, Agios said it was aware of the report and confirmed that three of the four cases had already been submitted to the FDA through standard pharmacovigilance processes.&nbsp;Two patients involved&nbsp;were treated with Pyrukynd for pyruvate kinase deficiency under its approved U.S. indication, while one patient with sickle cell disease&nbsp;was treated through expanded access.&nbsp;The fourth case had been reported directly to the FDA, and Agios said it is currently evaluating it.The company added that, to date, the available information does not change Pyrukynd’s benefit-risk profile as represented in its U.S. prescribing information.A regulatory decision on Pyrukynd for thalassemia is due from the U.S. FDA by Sept. 7. Additional filings are under review in the UAE and European Union.On Stocktwits, retail sentiment for Agios was ‘bullish’ amid ‘extremely high’ message volume.One user acknowledged not being bullish on the stock but noted that each reported death involved patients with severe underlying conditions.&nbsp;“Two were dealing with sickle cell complications, one was 93 and already critically ill — none were stable patients simply adding Pyrukynd to an existing regimen,” the user wrote, suggesting the outcomes may not reflect typical treatment scenarios.&nbsp;<stembedurl>https://stocktwits.com/Dkll303/message/623704770</stembedurl>Another user focused on the day’s sharp intraday recovery, and said the stock had an “absolutely incredible recovery.”<stembedurl>https://stocktwits.com/yachtsandthots/message/623705222</stembedurl>Agios’ stock has risen 13.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail chatter around Agios Pharmaceuticals (AGIO) spiked Tuesday after the company said that Saudi Arabia’s Food and Drug Authority (SFDA) approved Pyrukynd. (Photo credit: Getty Images)

Agios Retail Buzz Surges On Saudi Thalassemia Nod As Retail Hails ‘Incredible Recovery’ Despite FDA Concerns

Retail investors defended Agios on Stocktwits, saying reported deaths involved critically ill patients and didn’t reflect typical use. 

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -10.92% and +34.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$43.24
Prev Close	$43.18
Open	$42.86
Dividend Yield	0.00%
50-Day Moving Average	$39.58
Beta	1.24
Avg. Volume	806,876.00
PE Ratio	-6.22

52-Week High	$62.58
52-Week Low	$23.42
Market Capitalization	$2.51B
EPS (Annual)	$11.64
Price to Book	1.83
Revenue Per Employee	$74,790.98
Enterprise Value/EBITDA	N/A

AGIO
Agios Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AGIO News

AGIOAgios Pharmaceuticals Inc